Human leukemia cell lines are of great value in investigating basic and applied aspects of cell biology and clinical medicine. There have been 37 leukemia cell lines carrying 11q23 translocation and MLL rearrangements; however, cell lines harboring with t(1;11)(p32;q23) have not been established. We report here for the first time a new acute monocytic leukemia (AMoL) cell line with t(1;11)(p32;q23), designated TZ-1, and herein describe its biological characteristics. Mononuclear cells isolated from the ascites from a patient with AMoL (French-American-British classification; acute myeloid leukemia M5a) were isolated and passaged by liquid culture medium for a year. TZ-1 cells revealed typical monocytic features in morphology and had a t(1;11)(p32;q23) translocation. The immunoprofiling as determined by flow cytometry showed that TZ-1 cells are positive for myeloid and monocytic markers with lymphoid-associated markers. Fluorescence in situ hybridization and reverse transcription-polymerase chain reaction analyses revealed MLL-EPS15 fusion transcript and protein. Taken together, these results suggest that TZ-1 is a new monocytic leukemia cell line with t(1;11) translocation and fusion gene MLL-EPS15. The established cell line, TZ-1, could provide a valuable model in the analysis of the pathogenesis of MLL-EPS15-positive leukemia and in the development of new agents for this type of leukemia.
Introduction
The MLL gene is located on chromosome 11 band q23 and is frequently rearranged by chromosome translocation in acute myeloid leukemia (AML), myelodysplastic syndrome and acute lymphoblastic leukemia. 1 In children, almost 50% of acute monoblastic leukemia (AML, M5 subtype in FrenchAmerican-British (FAB) classification) cases involve a rearrangement of chromosome 11q23, particularly the MLL gene; however, the frequency of MLL rearrangement is 31% and only 12% in adult AML M5a and M5b subtypes, respectively. [2] [3] [4] More than 60 partner genes for MLL to generate fusion proteins have been reported and thought to be critical for leukemogenesis. 5, 6 There are several hundreds of leukemia cell lines, but almost 50% of them are not very well characterized, only 37 cell lines carrying 11q23 translocation have been developed. 6 These include 16 cell lines with t(4;11)(q21;q23), eight with t(11;19)(q23;p13), seven with t(9;11)(p22;q23), three with t(6;11)(q27;q23), and one with t(5;11)(q15;q23), t(11;16) (q23;p13) and t(X;11)(q13;q23). 6 However, cell lines with 11q23 translocation including t(1;11)(p32;q23) have not been reported. Acute leukemia carrying 11q23 translocations and MLL fusion protein can be classified into two clinical subgroups: infant leukemia and therapy-related leukemia that usually occurs after treatment with DNA topoisomerase 2 inhibitors. 7 In general, the prognosis of patients with MLL rearrangements is poor, and median survival was reported to be 8.9 months. 8 We have recently established a novel human cell line, designated as TZ-1, from a patient with acute monocytic leukemia (AMoL). We established this cell line from an ascites sample in the relapse. It exhibited t(1;11)(p32;q23) and the rearrangement of the MLL gene. This is the first cell line with translocation including t(1;11)(p32;q23).
Materials and methods

Case report
A 76-year-old Japanese man was admitted to our hospital because of general malase and appetite loss in March 2004. He was diagnosed with liver cirrhosis in 1996 followed by hepatic cell carcinoma. He underwent partial resection of the liver and transcatheter arterial embolization in 2003; however, he has never received chemotherapy or radiotherapy. Physical examination revealed large hepatomegaly (8 cm below the left costal margin) and slight anemia. His hemoglobin concentration was 10 g/dl, his white blood cell count was 2.0 Â 10 9 /l with 1% monoblasts and promonocytes, and his platelet count was 68 Â 10 9 /l. Bone marrow examination showed hypercellular marrow with 82.6% monoblasts and 11.0% promonocytes, which had folded nuclei, prominent nucleoli, finely reticular chromatin and abundant blue-gray cytoplasm. These cells were negative for myeloperoxidase (MPO) staining and positive for a-naphthyl butyrate esterase staining. Leukemic cells expressed CD13, CD14, CD33, CD38 and histocompatibility leukocyte antigen (HLA)-DR, but were negative for lymphoid antigens (CD3, CD10 and CD19). However, CD7 and CD56 were aberrantly positive. The patient was diagnosed as having AML M5a according to the FAB criteria. He was treated with low doses of cytosine arabinoside and aclarubicin, and once achieved complete remission in October 2004. Since then, he relapsed and finally died of refractory leukemia 13 months after the initial diagnosis.
Cell culture
Mononuclear cells from an ascites sample withdrawn with written informed consent in February 2005 during the relapse were separated by Lymphoprep (Nycomed Pharma AS, Oslo, Norway) and cultured in a six-well plate at a density of 5 Â 10 5 cells/ml in RPMI1640 culture medium (Sigma, St Louis, MO, USA) supplemented with 20% fetal bovine serum (Sigma), 100 U/ml penicillin and 100 mg/ml streptomycin in a humidified atmosphere with 5% CO 2 . The medium was exchanged every 3-4 days depending on the rate of cell growth.
Morphological, cytochemical and transmission electron microscopic studies
Light microscopy examination was performed on WrightGiemsa-stained cytospin preparations. Cytochemical staining for MPO, a-naphthyl butyrate esterase and a-naphthyl acetate esterase were also performed by standard methodology.
For observation of detailed cell morphology and intracellular structure on the transmission electron microscope (TEM), cell preparations were fixed with 2.5% glutaraldehyde and 2% paraformaldehyde. For electron immunophenotyping, pre-embedded immunogold labeling was used to determine antigen expression on the cell surface. Cells were pelleted in phosphatebuffered saline containing 0.5 ml 1% egg albumin for 30 min and then incubated with a 1:100 dilution of MY9 (CD33), MY4 (CD14) (Beckman Coulter, Fullerton, CA, USA) and CBL161 (CD20) (Chemicon, Temecula, CA, USA) for 60 min. Goldconjugated self-assembled monolayers immunoglobulin (Ig)G, gold-conjugated goat anti-mouse (GAM) IgM antibody was added for 30 min at 41C. The specimens were processed, sectioned and examined with a TEM to determine gold particlelabeled antigens on the cell surface.
Cell surface marker analysis
Surface immunophenotyping of the primary leukemia cells and TZ-1 cell lines was performed by flow cytometry using a broad panel of monoclonal antibodies. The cells were analyzed on a flow cytometer for fluorescence intensity using fluorescein isothiocyanate-or phycoerythrin-conjugated antibodies. All monoclonal antibodies used were purchased from Beckman Coulter (Fullerton, CA, USA) and Becton Dickinson (Franklin Lakes, NJ, USA).
Cytogenetic analysis
Chromosomes of both the primary leukemia cells and the TZ-1 cells were analyzed. Chromosomes were prepared by a standard method and banded by the G-banding technique. The karyotypic abnormalities were identified according to the International System for Human Cytogenetic Nomenclature (ISDN 1995).
Fluorescence in situ hybridization assay
Fluorescence in situ hybridization (FISH) analysis was performed using the dual-color probe as described previously. 9 MLL probe (red) covered both the 5 0 -and 3 0 regions of the MLL gene, and the EPS15 probe (green) matched approximately 140 kb including the 5 0 region of the EPS15 gene.
Reverse transcription-polymerase chain reaction analysis
Total cellular RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Ten pmol of primers for MLL 11q23 exon 10 (
0 ) and EPS15 exon 6 (5 0 -CTGCAGAGGTTCCACTG ATT-3 0 ) were used in the reaction. MLL exon 5 and EPS15 exon 6 were used to amplify the MLL-EPS15 fusion transcript (680 bp), whereas EPS15 exon 1 and MLL exon 10 were used to amplify the EPS15-MLL reciprocal fusion transcript (474 bp). 10 After an initial denaturation at 941C for 9 min, 35 cycles of 1 min at 941C, 1 min at 561C, 90 s at 721C and final extension at 721C for 7 min were performed in Takara RNA PCR Kit (AMV, ver. 3.0) (Takara, Tokyo, Japan). The PCR products were electrophoresed in 2% agarose gels. An aliquot of cDNA reagents from a normal individual was amplified by PCR as a negative control.
Direct sequencing
cDNA extracted from TZ-1 cells was amplified by PCR using MLL exon 5 and EPS15 exon 6 primers as described in the Materials and methods sections. DNA fragments amplified by PCR were purified, concentrated and sequenced with BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and an automated sequencer ABI PRISM 310 Genetic Analyzer (Applied Biosystems). Sequencing primer was used as same as MLL exon 5 primer for reverse transcription-polymerase chain reaction (RT-PCR).
Detection of Epstein-barr virus
Real-time PCR was performed to detect Epstein-barr virus (EBV) genomic DNA according to the manufacturer's instructions.
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The genomic DNA was extracted from the cell line and amplified using EBV-specific primer pairs in an ABI PRISM 7700 Real-time thermal cycler (Applied Biosystems).
Results
Establishment of the TZ-1 cell line
Two months after the beginning of the culture, the cells showed slow but stable proliferation. The cells started to proliferate rapidly after 3 months. The cells were grown in a continuous culture for more than a year, and we thus judged them as a continuous cell line and designated as TZ-1. TZ-1 cell line remained stable during this culture period and also after repeated freezing and thawing. The TZ-1 cells showed a growth pattern in suspension as single cells, and had a doubling time of 36 h in complete medium.
Morphology of TZ-1 cells
TZ-1 cells show a regular cell shape, folded nucleus with prominent nucleoli, finely reticular chromatin and blue-gray cytoplasm, which were similar to those of the primary leukemia cells (Figure 1a) . TZ-1 cells were positive for a-naphthyl butyrate esterase and the NaF-inhibition test, whereas negative for a-naphthyl acetate esterase and MPO staining (data not shown). TEM examination of TZ-1 cells shows an oval cell shape, folded nucleus containing clumped chromatin with prominent nucleoli. Many free ribosome, strands of rough endoplasmic reticulum, mitochondria and vacuoles were present in the cytoplasm (Figure 1b ). Immunoelectron microscopic analysis shows that TZ-1 cell are positive for MPO, CD33, CD14 and CD20 antigens (Figure 1b-d , and data not shown). These electron microscopic analyses suggest that morphological characters of TZ-1 cells are consistent with those of monocytic lineage cells.
Immunophenotypic profiles
The immunophenotypic profiles of the primary leukemia cells (bone marrow on diagnosis and ascites in relapse) and the TZ-1 AMoL with t(1;11) and fusion gene MLL-EPS15 M Sagawa et al cell line are summarized in Table 1 . Some of them had similar immunophenotypic profiles, such as CD13, CD14, CD33, CD34, CD38, HLA-DR and MPO. A few markers of T-lymphocytic lineage (CD7) were also present, whereas a few markers of erythroid lineage (CD235a) and megakaryocytic lineage (CD41) were absent. Moreover, primary cells from ascites newly expressed T-lymphocytic lineage marker CD5 (o1-38%), and B-lymphocytic lineage markers CD10 (6-87%) and CD20 (o1-30%), whereas TZ-1 cells sustained these phenotypes. However, CD4 (98-2%) and natural killer lineage marker CD56 (99-8%) were lost in TZ-1 cells.
Cytogenetics
The primary leukemia cells showed hyperdiploidity, t(1;11)(p32;q23) translocation, þ der(1) t(1;11) and þ 6, þ 8, þ 8, þ 13, þ 15, þ 17, þ 19, þ 21. TZ-1 cells had almost the same karyotype features with the addition of add(3) (p11), suggesting that TZ-1 cell line is derived from this patient. A karyotypic analysis of the TZ-1 cells is presented in Figure 2 .
FISH
Because t(1;11)(p32;q23) has been considered to produce a chimeric transcript with MLL and EPS15 genes located on chromosomes 11q23 and 1p32, FISH analysis was performed with MLL probe (red) and EPS15 probe (green). Dual-color FISH analysis in Figure 3 showed a split of MLL-EPS15 translocation and a few der(1) t(1;11), der(11) t(1;11).
RT-PCR
RT-PCR using MLL and EPS15 sequence-specific primers was performed on total RNA from TZ-1 cells. Expected MLL-EPS15 fusion transcript (680 bp) and its reciprocal EPS15-MLL fusion transcript (474 bp) could be detected in the TZ-1 cells (Figure 4) . AMoL with t(1;11) and fusion gene MLL-EPS15 M Sagawa et al
Direct sequencing
As shown in Figure 5 , sequence analysis of the DNA fragments amplified by PCR showed the breakpoint of MLL-EPS15 fusion gene. The breakpoint was located in exon 6 of MLL, which fused to exon 2 of EPS15. This breakpoint was the same as the previously reported case. 10 There was no mutation or deletion in the part of MLL and EPS15 genes included in their chimeric transcript.
Detection of EBV
EBV genomic DNA was negative in TZ-1 cells using quantitative PCR (data not shown). It proved that the addition of the B-cell phenotype of TZ-1 cells is not a contamination of EBV.
Discussion
In the present study, we describe a novel cell line, TZ-1, established from a patient with AMoL (AML M5a in FAB classification), which was demonstrated by morphological, cytochemical and immunological characteristics, such as regular cell shape, folded nucleus with prominent nucleoli, finely reticular chromatin, blue-gray cytoplasm morphology, positive MPO staining only at electron microscopic analysis, positive a-naphthyl esterase staining and expression of the myeloid and monocytic surface markers (CD13, CD14, CD33, CD38 and HLA-DR). This patient had unique t(1;11)(p32;q23) translocation. FISH analysis demonstrated t(1;11) MLL rearrangement, and RT-PCR and sequence analysis also proved the MLL-EPS15 fusion transcript. Rearrangements of the MLL gene, usually involved in translocations, occur in 5-10% of AML. 12 Translocations between band 11q23 and chromosome 1 have been described, and rearrangement of MLL has been identified in a few cases. [13] [14] [15] [16] [17] It has reported that the breakpoints on chromosome 1 are located in bands p36, p32, p13 and q21. 12 At present, 37 cell lines carrying MLL rearrangements have been developed; however, there are no cell lines involving t(1;11) translocations. Therefore, TZ-1 is the first cell line with t(1;11) MLL rearrangement.
It was reported that the MLL gene was fused to the EPS15 gene in a patient with t(1;11)(p32;q23).
10 EPS15 was originally discovered as a substrate of the epidermal growth factor (EGF) receptor tyrosine kinase, 18 and encoded by the murine EGF pathway substrate 15 (EPS15) gene. 10 This cytoplasmic protein can be phosphorylated on tyrosine residues following activation of the EGF receptor and platelet-derived growth factor (PDGF) receptor. 18, 19 The human homolog was cloned and mapped to 1p31-p32. 20 It contains coiled-coil domains that mediate homo-oligomerization and are necessary and sufficient for the activation of MLL. Furthermore, dimerization of MLL-EPS15 fusion recruits accessory factors through MLL moiety, resulting in Hox gene activation and enhanced self-renewal of hematopoietic progenitors. 21 It is also reported that Hoxa7 and Hoxa9 genes are related in that they transformed myeloid progenitors 22 and promoted transcription and multiple histone modifications. 23 Further investigation is necessary to address the molecular mechanism of MLL-EPS15 leukemia, and this cell line could be a useful and effective tool to investigate the oncogenic mechanism of MLL leukemia.
In conclusion, the TZ-1 cell line is a novel cell line with MLL-EPS15 translocations, and could be a useful tool for further investigating MLL leukemia. Therefore, the authors are willing to release the TZ-1 cell line to investigators in the world.
